Programmable Release of Chemotherapeutics from Ferrocene‐Based Injectable Hydrogels Slows Melanoma Growth

• DOI: 10.1002/adhm.202400265
• Publication Date: 2024-07-15T09:56:17Z
• Authors: Rebecca Rothe; Yong Xu; Johanna Wodtke; Florian Brandt; Sebastian Meister; Markus Laube; Pier‐Luigi Lollini; Yixin Zhang; Jens Pietzsch; Sandra Hauser
• Keywords: Biocompatibility

Abstract Hydrogel‐based injectable drug delivery systems provide temporally and spatially controlled release with reduced adverse effects on healthy tissues. Therefore, they represent a promising therapeutic option for unresectable solid tumor entities. In this study, peptide‐starPEG/hyaluronic acid‐based physical hydrogel is modified ferrocene to programmable orchestrated by matrix‐drug interaction local reactive oxygen species (ROS). The ROS‐responsive (hiROSponse) exhibits adequate biocompatibility biodegradability, which are important clinical applications. HiROSponse loaded the two cytostatic drugs (hiROSponse dox/ptx ) doxorubicin (dox) paclitaxel (ptx). Dox hydrophilic compound its mainly Fickian diffusion, while hydrophobic interactions between ptx can control thus be regulated oxidation of more state ferrocenium. syngeneic malignant melanoma‐bearing mouse model, hiROSponse slows growth without causing side doubles relative survival probability. Programmable further demonstrated in model low physiological ROS level, where dox release, dose irradiation, resulting ROS‐triggered lead inhibition increased survival.